Trial Condition(s):

Myocardial Infarction

Depiction of delayed enhancement in patients with documented myocardial infarction

Bayer Identifier:

91230

ClinicalTrials.gov Identifier:

NCT00310544

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The purpose of this study is to determine the dose of drug which is most effective in the delineation of dead heart muscle.

Inclusion Criteria
- At least 8 weeks post-documented myocardial infarction (heart attack)
Exclusion Criteria
- History of radiation therapy to the chest
 - Clinically unstable
 - Any contraindication for MRI

Trial Summary

Enrollment Goal
73
Trial Dates
black-arrow
Phase
2
Could I receive a placebo?
No
Products
Magnevist (Gadopentetate Dimeglumine, BAY86-4882)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Allegheny General Hospital

Pittsburgh, United States, 15212-4772

Status
Completed
 
Locations

Pennsylvania State University College of Medicine

Hershey, United States, 17033

Status
Completed
 
Locations

Forsyth Radiologcial Associates, PA

Winston-Salem, United States, 27103

Status
Completed
 
Locations

Oklahoma Heart Institute

Tulsa, United States, 74133

Status
Completed
 
Locations

University of California-San Diego Medical Center

San Diego, United States, 92103

Status
Completed
 
Locations

Oregon Health and Science University

Portland, United States, 97239

Status
Completed
 
Locations

Centro de Diagnóstico Dr. Enrique Rossi

Buenos Aires, Argentina, C1428BKN

Status
Completed
 

Trial Design